Synergistic effects of amyloid-beta and wild-type human tau on dendritic spine loss in a floxed double transgenic model of Alzheimer's disease

Neurobiology of Disease

Volumn 64, Issue , 2014, Pages 107-117

  Chabrier, Meredith A ^a,b   Cheng, David ^a,b   Castello, Nicholas A ^a,b   Green, Kim N ^a,b,c   LaFerla, Frank M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

Alzheimer's disease; Dendritic spines; Transgenic; Wild type tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CRE RECOMBINASE; OLIGOMER; TAU PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TASK PERFORMANCE;

ALZHEIMER'S DISEASE; DENDRITIC SPINES; TRANSGENIC; WILD-TYPE TAU;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CA1 REGION, HIPPOCAMPAL; COGNITION DISORDERS; DENDRITIC SPINES; DISEASE PROGRESSION; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FYN; PYRAMIDAL CELLS; SYNAPSES; TAU PROTEINS;

EID: 84892966799     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.01.007     Document Type: Article

References (37)

1. Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13594-13599.
2. Carlson G.A., Borchelt D.R., Dake A., Turner S., Danielson V., Coffin J.D., Eckman C., Meiners J., Nilsen S.P., Younkin S.G., Hsiao K.K. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum. Mol. Genet. 1997, 6:1951-1959.
3. Caroni P. Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J. Neurosci. Methods 1997, 71:3-9.
4. Chabrier M.A., Blurton-Jones M., Agazaryan A.A., Nerhus J.L., Martinez-Coria H., LaFerla F.M. Soluble abeta promotes wild-type tau pathology in vivo. J. Neurosci. 2012, 32:17345-17350.
5. Chen Y., Rex C.S., Rice C.J., Dube C.M., Gall C.M., Lynch G., Baram T.Z. Correlated memory defects and hippocampal dendritic spine loss after acute stress involve corticotropin-releasing hormone signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13123-13128.
6. Chin J., Palop J.J., Yu G.Q., Kojima N., Masliah E., Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 2004, 24:4692-4697.
7. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27:457-464.
8. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006, 26:6011-6018.
9. Dickstein D.L., Brautigam H., Stockton S.D., Schmeidler J., Hof P.R. Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct. Funct. 2010, 214:161-179.
10. Gotz J., Probst A., Spillantini M.G., Schafer T., Jakes R., Burki K., Goedert M. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 1995, 14:1304-1313.
11. Gotz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001, 276(1):529-534.
12. Holtmaat A., Wilbrecht L., Knott G.W., Welker E., Svoboda K. Experience-dependent and cell-type-specific spine growth in the neocortex. Nature 2006, 441:979-983.
13. Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.L., Ashe K.H., Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010, 68:1067-1081.
14. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
15. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
16. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron 2003, 37:925-937.
17. Kasai H., Matsuzaki M., Noguchi J., Yasumatsu N., Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci. 2003, 26:360-368.
18. Koffie R.M., Hyman B.T., Spires-Jones T.L. Alzheimer's disease: synapses gone cold. Mol. Neurodegener. 2011, 6:63.
19. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
20. Larson M.E., Lesne S.E. Soluble Abeta oligomer production and toxicity. J. Neurochem. 2012, 120(Suppl. 1):125-139.
21. Lee G., Newman S.T., Gard D.L., Band H., Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 1998, 111(Pt 21):3167-3177.
22. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
23. Mairet-Coello G., Courchet J., Pieraut S., Courchet V., Maximov A., Polleux F. The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron 2013, 78:94-108.
24. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001, 293(5534):1487-1491.
25. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
26. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
27. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39(3):409-421.
28. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43(3):321-332.
29. Oddo S., Caccamo A., Cheng D., Jouleh B., Torp R., LaFerla F.M. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J. Neurochem. 2007, 102:1053-1063.
30. Perez-Cruz C., Nolte M.W., van Gaalen M.M., Rustay N.R., Termont A., Tanghe A., Kirchhoff F., Ebert U. Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:3926-3934.
31. Pillai J.A., Cummings J.L. Clinical trials in predementia stages of Alzheimer disease. Med. Clin. North Am. 2013, 97:439-457.
32. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
33. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
34. Salter M.W., Kalia L.V. Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 2004, 5:317-328.
35. Spires T.L., Meyer-Luehmann M., Stern E.A., McLean P.J., Skoch J., Nguyen P.T., Bacskai B.J., Hyman B.T. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005, 25:7278-7287.
36. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
37. Zempel H., Thies E., Mandelkow E., Mandelkow E.M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010, 30:11938-11950.